| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mouth Neoplasms | 44 | 2023 | 194 | 9.270 |
Why?
|
| Carcinoma, Squamous Cell | 72 | 2023 | 1076 | 8.040 |
Why?
|
| Head and Neck Neoplasms | 54 | 2023 | 1052 | 6.040 |
Why?
|
| Precancerous Conditions | 16 | 2020 | 196 | 2.960 |
Why?
|
| Neovascularization, Pathologic | 25 | 2013 | 353 | 2.430 |
Why?
|
| Periodicals as Topic | 8 | 2016 | 168 | 2.370 |
Why?
|
| Biomarkers, Tumor | 26 | 2022 | 1464 | 2.020 |
Why?
|
| Papillomavirus Infections | 13 | 2023 | 239 | 1.970 |
Why?
|
| Mass Screening | 12 | 2016 | 618 | 1.920 |
Why?
|
| Education, Dental | 4 | 2017 | 8 | 1.440 |
Why?
|
| Pathology, Oral | 4 | 2021 | 5 | 1.230 |
Why?
|
| Early Detection of Cancer | 12 | 2021 | 394 | 1.220 |
Why?
|
| Oral Medicine | 3 | 2016 | 4 | 1.210 |
Why?
|
| Humans | 168 | 2023 | 86643 | 1.130 |
Why?
|
| Saliva | 6 | 2021 | 122 | 1.040 |
Why?
|
| American Dental Association | 5 | 2019 | 9 | 0.960 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2021 | 62 | 0.940 |
Why?
|
| Alphapapillomavirus | 4 | 2021 | 45 | 0.930 |
Why?
|
| Oropharyngeal Neoplasms | 6 | 2022 | 118 | 0.920 |
Why?
|
| Gene Expression Regulation, Neoplastic | 13 | 2018 | 1197 | 0.920 |
Why?
|
| Plagiarism | 5 | 2013 | 8 | 0.900 |
Why?
|
| Papillomaviridae | 9 | 2022 | 153 | 0.820 |
Why?
|
| Angiogenesis Inhibitors | 6 | 2009 | 311 | 0.820 |
Why?
|
| Editorial Policies | 5 | 2016 | 32 | 0.810 |
Why?
|
| Leukoplakia, Oral | 5 | 2021 | 11 | 0.790 |
Why?
|
| Nuclear Proteins | 6 | 2017 | 696 | 0.750 |
Why?
|
| Promoter Regions, Genetic | 3 | 2012 | 937 | 0.720 |
Why?
|
| Salivary Gland Neoplasms | 5 | 2019 | 66 | 0.710 |
Why?
|
| Tretinoin | 5 | 2002 | 126 | 0.710 |
Why?
|
| Students, Dental | 2 | 2011 | 4 | 0.690 |
Why?
|
| Publishing | 3 | 2014 | 90 | 0.670 |
Why?
|
| Endothelium, Vascular | 9 | 2006 | 435 | 0.650 |
Why?
|
| Neovascularization, Physiologic | 7 | 2004 | 133 | 0.640 |
Why?
|
| Medicare | 1 | 2021 | 410 | 0.630 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2010 | 157 | 0.630 |
Why?
|
| Surgery, Oral | 2 | 2015 | 19 | 0.610 |
Why?
|
| ErbB Receptors | 11 | 2017 | 485 | 0.600 |
Why?
|
| Histone-Lysine N-Methyltransferase | 4 | 2023 | 154 | 0.600 |
Why?
|
| Schools, Dental | 1 | 2017 | 7 | 0.600 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2012 | 279 | 0.590 |
Why?
|
| Journalism, Dental | 2 | 2013 | 2 | 0.570 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 11 | 2022 | 2438 | 0.560 |
Why?
|
| Mouth | 5 | 2021 | 48 | 0.550 |
Why?
|
| Publications | 2 | 2013 | 27 | 0.550 |
Why?
|
| Loss of Heterozygosity | 4 | 2017 | 85 | 0.530 |
Why?
|
| Carcinoma, Verrucous | 2 | 2015 | 7 | 0.520 |
Why?
|
| Vascular Endothelial Growth Factor A | 11 | 2009 | 407 | 0.520 |
Why?
|
| Immunohistochemistry | 17 | 2020 | 1753 | 0.510 |
Why?
|
| Tissue Array Analysis | 7 | 2017 | 124 | 0.500 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 4 | 2015 | 27 | 0.490 |
Why?
|
| Gene Expression Profiling | 11 | 2015 | 1384 | 0.490 |
Why?
|
| Sensitivity and Specificity | 9 | 2021 | 1991 | 0.490 |
Why?
|
| Cytological Techniques | 2 | 2011 | 30 | 0.490 |
Why?
|
| Macrophages | 6 | 2017 | 554 | 0.480 |
Why?
|
| Wound Healing | 5 | 2006 | 344 | 0.470 |
Why?
|
| Female | 60 | 2022 | 44532 | 0.470 |
Why?
|
| Tongue Neoplasms | 4 | 2012 | 50 | 0.470 |
Why?
|
| Antigens, CD34 | 1 | 2013 | 158 | 0.460 |
Why?
|
| Cytodiagnosis | 3 | 2012 | 42 | 0.460 |
Why?
|
| Cell Movement | 10 | 2016 | 758 | 0.450 |
Why?
|
| Animals | 47 | 2022 | 26582 | 0.450 |
Why?
|
| Keratinocytes | 7 | 2011 | 143 | 0.440 |
Why?
|
| Retinoblastoma Protein | 1 | 2012 | 66 | 0.440 |
Why?
|
| United States | 11 | 2021 | 6672 | 0.420 |
Why?
|
| Palatine Tonsil | 1 | 2011 | 30 | 0.410 |
Why?
|
| Actins | 2 | 2013 | 451 | 0.400 |
Why?
|
| Cervix Uteri | 1 | 2011 | 65 | 0.400 |
Why?
|
| Mice | 28 | 2021 | 11352 | 0.400 |
Why?
|
| Vaginal Smears | 1 | 2011 | 68 | 0.400 |
Why?
|
| Chemoradiotherapy | 6 | 2022 | 301 | 0.400 |
Why?
|
| Cell Transformation, Neoplastic | 6 | 2018 | 427 | 0.400 |
Why?
|
| Biomarkers | 6 | 2017 | 1718 | 0.390 |
Why?
|
| Cell Nucleolus | 2 | 2010 | 23 | 0.380 |
Why?
|
| Tumor Cells, Cultured | 11 | 2018 | 1041 | 0.380 |
Why?
|
| Herpesvirus 1, Human | 4 | 1997 | 244 | 0.380 |
Why?
|
| Male | 44 | 2022 | 40965 | 0.370 |
Why?
|
| Algorithms | 2 | 2018 | 1830 | 0.370 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2010 | 15 | 0.370 |
Why?
|
| Quinazolines | 5 | 2012 | 220 | 0.370 |
Why?
|
| Evidence-Based Dentistry | 3 | 2017 | 10 | 0.360 |
Why?
|
| Disease Models, Animal | 7 | 2016 | 2232 | 0.360 |
Why?
|
| Hyperplasia | 3 | 2023 | 148 | 0.350 |
Why?
|
| Marketing of Health Services | 1 | 2009 | 15 | 0.340 |
Why?
|
| Protein Kinase Inhibitors | 7 | 2017 | 589 | 0.340 |
Why?
|
| Cell Line, Tumor | 13 | 2015 | 2426 | 0.340 |
Why?
|
| Consumer Health Information | 1 | 2009 | 13 | 0.340 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2015 | 275 | 0.330 |
Why?
|
| Middle Aged | 32 | 2022 | 25028 | 0.330 |
Why?
|
| Carcinoma | 2 | 2022 | 436 | 0.330 |
Why?
|
| DNA, Viral | 3 | 2022 | 265 | 0.330 |
Why?
|
| Organizational Affiliation | 1 | 2008 | 6 | 0.330 |
Why?
|
| Viral Envelope Proteins | 4 | 1996 | 94 | 0.330 |
Why?
|
| Antineoplastic Agents | 8 | 2018 | 2360 | 0.330 |
Why?
|
| Organizations, Nonprofit | 1 | 2008 | 8 | 0.320 |
Why?
|
| Point-of-Care Systems | 1 | 2009 | 141 | 0.320 |
Why?
|
| Inflammation | 2 | 2006 | 920 | 0.320 |
Why?
|
| Endothelial Growth Factors | 4 | 2002 | 55 | 0.320 |
Why?
|
| Lymphokines | 4 | 2002 | 76 | 0.320 |
Why?
|
| Marketing | 1 | 2008 | 23 | 0.320 |
Why?
|
| Angiogenic Proteins | 1 | 2008 | 17 | 0.320 |
Why?
|
| Oligopeptides | 1 | 2009 | 179 | 0.320 |
Why?
|
| Organizations | 1 | 2007 | 17 | 0.310 |
Why?
|
| Proto-Oncogene Proteins c-met | 4 | 2018 | 199 | 0.310 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2012 | 689 | 0.300 |
Why?
|
| Aged | 23 | 2021 | 18415 | 0.300 |
Why?
|
| Risk Factors | 11 | 2019 | 5417 | 0.290 |
Why?
|
| Epigenesis, Genetic | 1 | 2011 | 479 | 0.290 |
Why?
|
| 4-Nitroquinoline-1-oxide | 7 | 2021 | 15 | 0.290 |
Why?
|
| Deception | 1 | 2006 | 20 | 0.290 |
Why?
|
| Interferon Type I | 3 | 2023 | 175 | 0.290 |
Why?
|
| Endothelial Cells | 7 | 2012 | 428 | 0.290 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2020 | 104 | 0.280 |
Why?
|
| Gene Deletion | 3 | 2014 | 329 | 0.280 |
Why?
|
| Point Mutation | 2 | 2019 | 246 | 0.270 |
Why?
|
| Rad51 Recombinase | 1 | 2006 | 80 | 0.270 |
Why?
|
| Interleukin-8 | 6 | 2012 | 86 | 0.260 |
Why?
|
| Transforming Growth Factor beta | 4 | 2006 | 301 | 0.260 |
Why?
|
| Clinical Competence | 1 | 2011 | 751 | 0.260 |
Why?
|
| Neoplasms | 5 | 2013 | 2898 | 0.260 |
Why?
|
| Neoplasm Grading | 2 | 2019 | 357 | 0.250 |
Why?
|
| Attitude of Health Personnel | 1 | 2010 | 636 | 0.250 |
Why?
|
| Tumor Virus Infections | 2 | 2015 | 81 | 0.250 |
Why?
|
| Prognosis | 11 | 2022 | 3679 | 0.250 |
Why?
|
| Carcinogens | 6 | 2021 | 108 | 0.250 |
Why?
|
| Adult | 26 | 2022 | 25648 | 0.250 |
Why?
|
| Human papillomavirus 16 | 3 | 2014 | 38 | 0.250 |
Why?
|
| Neoplasm Staging | 9 | 2018 | 1939 | 0.240 |
Why?
|
| Receptor, EphB4 | 2 | 2014 | 24 | 0.240 |
Why?
|
| New Orleans | 1 | 2023 | 6 | 0.230 |
Why?
|
| Psoriasis | 1 | 2006 | 240 | 0.230 |
Why?
|
| Plasminogen Activator Inhibitor 2 | 1 | 2003 | 2 | 0.230 |
Why?
|
| Carcinoma, Mucoepidermoid | 2 | 2019 | 17 | 0.230 |
Why?
|
| Adenoma, Pleomorphic | 2 | 2019 | 6 | 0.230 |
Why?
|
| Phenotype | 10 | 2012 | 2378 | 0.220 |
Why?
|
| Apoptosis | 6 | 2016 | 1683 | 0.220 |
Why?
|
| Osteoradionecrosis | 1 | 2022 | 18 | 0.220 |
Why?
|
| Cell Line | 9 | 2012 | 2468 | 0.220 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 3 | 2015 | 81 | 0.220 |
Why?
|
| Mutation | 10 | 2020 | 3968 | 0.220 |
Why?
|
| DNA, Neoplasm | 3 | 2020 | 265 | 0.220 |
Why?
|
| Re-Irradiation | 1 | 2022 | 15 | 0.220 |
Why?
|
| Mouth Mucosa | 8 | 2018 | 67 | 0.220 |
Why?
|
| Cells, Cultured | 10 | 2017 | 2818 | 0.210 |
Why?
|
| Germ-Line Mutation | 2 | 2018 | 329 | 0.210 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2022 | 1313 | 0.210 |
Why?
|
| Developmental Disabilities | 2 | 2015 | 195 | 0.210 |
Why?
|
| Lymphatic Metastasis | 3 | 2019 | 486 | 0.210 |
Why?
|
| Gene Expression Regulation | 4 | 2015 | 1920 | 0.210 |
Why?
|
| Repressor Proteins | 3 | 2014 | 403 | 0.210 |
Why?
|
| Stomatitis | 2 | 2012 | 30 | 0.210 |
Why?
|
| Liquid Biopsy | 1 | 2021 | 33 | 0.210 |
Why?
|
| Peptide Hormones | 2 | 2012 | 29 | 0.200 |
Why?
|
| RNA, Viral | 2 | 2013 | 327 | 0.200 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2002 | 100 | 0.200 |
Why?
|
| Gene Knockdown Techniques | 4 | 2017 | 236 | 0.200 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2021 | 70 | 0.200 |
Why?
|
| Coloring Agents | 5 | 2021 | 64 | 0.200 |
Why?
|
| Erlotinib Hydrochloride | 3 | 2017 | 90 | 0.200 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2001 | 49 | 0.200 |
Why?
|
| Transfection | 5 | 2012 | 896 | 0.200 |
Why?
|
| Drug Monitoring | 1 | 2022 | 118 | 0.200 |
Why?
|
| Induction Chemotherapy | 3 | 2022 | 147 | 0.200 |
Why?
|
| Receptor, ErbB-2 | 2 | 2017 | 223 | 0.200 |
Why?
|
| Diagnosis, Differential | 5 | 2020 | 1565 | 0.190 |
Why?
|
| Mice, Nude | 7 | 2016 | 790 | 0.190 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2022 | 71 | 0.190 |
Why?
|
| Disease Progression | 7 | 2020 | 1531 | 0.190 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 298 | 0.180 |
Why?
|
| Genes, p53 | 1 | 2000 | 109 | 0.180 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2020 | 28 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2020 | 30 | 0.180 |
Why?
|
| Microvessels | 2 | 2011 | 70 | 0.180 |
Why?
|
| Thrombospondin 1 | 2 | 2012 | 21 | 0.180 |
Why?
|
| Gene Expression | 6 | 2016 | 1284 | 0.180 |
Why?
|
| Genome, Mitochondrial | 1 | 2019 | 26 | 0.180 |
Why?
|
| Behavioral Medicine | 1 | 2019 | 5 | 0.180 |
Why?
|
| Cetuximab | 2 | 2019 | 113 | 0.180 |
Why?
|
| Mice, Inbred CBA | 4 | 2018 | 52 | 0.180 |
Why?
|
| Signal Transduction | 10 | 2015 | 3241 | 0.170 |
Why?
|
| Retrospective Studies | 9 | 2020 | 8489 | 0.170 |
Why?
|
| Health Status | 2 | 2013 | 360 | 0.170 |
Why?
|
| Simplexvirus | 3 | 1995 | 151 | 0.170 |
Why?
|
| Myoepithelioma | 1 | 2019 | 11 | 0.170 |
Why?
|
| Chemoprevention | 4 | 2001 | 91 | 0.170 |
Why?
|
| Bone Substitutes | 1 | 2018 | 9 | 0.170 |
Why?
|
| Dental Implantation, Endosseous | 1 | 2018 | 10 | 0.170 |
Why?
|
| DNA, Mitochondrial | 1 | 2019 | 183 | 0.170 |
Why?
|
| Neoplasm Metastasis | 5 | 2020 | 1056 | 0.170 |
Why?
|
| Vascular Endothelial Growth Factors | 4 | 2002 | 56 | 0.170 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2018 | 14 | 0.170 |
Why?
|
| Dental Implants | 1 | 2018 | 10 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 6 | 2 | 2012 | 125 | 0.170 |
Why?
|
| Predictive Value of Tests | 4 | 2019 | 1673 | 0.170 |
Why?
|
| RNA, Messenger | 7 | 2014 | 1981 | 0.170 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2021 | 295 | 0.170 |
Why?
|
| Osteosarcoma | 1 | 2020 | 158 | 0.170 |
Why?
|
| Clinical Protocols | 1 | 2019 | 156 | 0.170 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2015 | 645 | 0.170 |
Why?
|
| Neutrophils | 2 | 2017 | 307 | 0.170 |
Why?
|
| DNA Repair | 2 | 2014 | 356 | 0.170 |
Why?
|
| Erythroplasia | 1 | 2018 | 1 | 0.160 |
Why?
|
| Gene Rearrangement | 1 | 2019 | 170 | 0.160 |
Why?
|
| Cell Nucleus | 4 | 2017 | 579 | 0.160 |
Why?
|
| Cricetinae | 6 | 2012 | 560 | 0.160 |
Why?
|
| Calcium Phosphates | 1 | 2018 | 77 | 0.160 |
Why?
|
| Genes, bcl-2 | 2 | 2016 | 16 | 0.160 |
Why?
|
| Guanine Nucleotide Exchange Factors | 2 | 2009 | 73 | 0.160 |
Why?
|
| DNA Copy Number Variations | 3 | 2015 | 171 | 0.150 |
Why?
|
| Coronary Vessels | 3 | 2014 | 177 | 0.150 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 123 | 0.150 |
Why?
|
| Amino Acids | 2 | 1995 | 252 | 0.150 |
Why?
|
| Cell Cycle Proteins | 3 | 2016 | 388 | 0.150 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2012 | 302 | 0.150 |
Why?
|
| Vulvovaginitis | 1 | 1997 | 3 | 0.150 |
Why?
|
| Tumor Microenvironment | 2 | 2019 | 418 | 0.150 |
Why?
|
| Lung Neoplasms | 3 | 2020 | 2262 | 0.150 |
Why?
|
| Cell Proliferation | 9 | 2018 | 1578 | 0.150 |
Why?
|
| Bone Neoplasms | 1 | 2020 | 322 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2017 | 36 | 0.150 |
Why?
|
| Base Sequence | 5 | 2014 | 2330 | 0.150 |
Why?
|
| Amino Acid Sequence | 6 | 2021 | 2062 | 0.150 |
Why?
|
| Real-Time Polymerase Chain Reaction | 6 | 2012 | 273 | 0.150 |
Why?
|
| Glucocorticoids | 2 | 2017 | 352 | 0.150 |
Why?
|
| Mandibular Neoplasms | 2 | 1995 | 24 | 0.150 |
Why?
|
| Lung Injury | 1 | 2017 | 47 | 0.150 |
Why?
|
| Lung | 4 | 2017 | 1170 | 0.150 |
Why?
|
| Gingival Diseases | 1 | 1996 | 1 | 0.150 |
Why?
|
| Keratoacanthoma | 1 | 1996 | 4 | 0.150 |
Why?
|
| Genes, ras | 1 | 1997 | 96 | 0.150 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2017 | 165 | 0.140 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2010 | 69 | 0.140 |
Why?
|
| Molecular Sequence Data | 5 | 2010 | 3030 | 0.140 |
Why?
|
| In Situ Hybridization, Fluorescence | 4 | 2020 | 348 | 0.140 |
Why?
|
| Oral Health | 2 | 2022 | 10 | 0.140 |
Why?
|
| Transcription, Genetic | 2 | 2012 | 1135 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2016 | 25 | 0.140 |
Why?
|
| Trans-Activators | 1 | 2019 | 429 | 0.140 |
Why?
|
| Cell Adhesion Molecules | 2 | 2014 | 163 | 0.140 |
Why?
|
| Manuscripts as Topic | 2 | 2013 | 4 | 0.140 |
Why?
|
| Transition to Adult Care | 1 | 2016 | 22 | 0.140 |
Why?
|
| Aged, 80 and over | 8 | 2019 | 6509 | 0.140 |
Why?
|
| Calgranulin A | 1 | 2016 | 11 | 0.140 |
Why?
|
| Calgranulin B | 1 | 2016 | 16 | 0.140 |
Why?
|
| Comparative Genomic Hybridization | 2 | 2015 | 39 | 0.140 |
Why?
|
| Arteritis | 1 | 2015 | 9 | 0.140 |
Why?
|
| Central Nervous System | 1 | 1997 | 151 | 0.140 |
Why?
|
| Mice, Inbred BALB C | 5 | 2018 | 1047 | 0.140 |
Why?
|
| Carboplatin | 3 | 2022 | 286 | 0.140 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2023 | 559 | 0.140 |
Why?
|
| Papillomavirus E7 Proteins | 2 | 2012 | 31 | 0.140 |
Why?
|
| Cocarcinogenesis | 1 | 2015 | 12 | 0.140 |
Why?
|
| Rats, Inbred F344 | 4 | 2001 | 156 | 0.140 |
Why?
|
| Lipopolysaccharides | 1 | 2017 | 286 | 0.140 |
Why?
|
| Oncogene Proteins, Viral | 2 | 2012 | 34 | 0.140 |
Why?
|
| Cell Transformation, Viral | 1 | 2015 | 40 | 0.140 |
Why?
|
| Transcription Factors | 2 | 2014 | 1565 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2012 | 879 | 0.130 |
Why?
|
| Dexamethasone | 1 | 2017 | 326 | 0.130 |
Why?
|
| Anticarcinogenic Agents | 1 | 2016 | 70 | 0.130 |
Why?
|
| Maxillary Sinus Neoplasms | 1 | 1995 | 8 | 0.130 |
Why?
|
| Nervous System Diseases | 1 | 2016 | 151 | 0.130 |
Why?
|
| Oncogenes | 1 | 2015 | 88 | 0.130 |
Why?
|
| Th17 Cells | 1 | 2016 | 80 | 0.130 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2015 | 153 | 0.130 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 3 | 2015 | 91 | 0.130 |
Why?
|
| Disease-Free Survival | 5 | 2018 | 1204 | 0.130 |
Why?
|
| Adolescent | 8 | 2022 | 8981 | 0.130 |
Why?
|
| Receptor, Notch1 | 1 | 2015 | 85 | 0.130 |
Why?
|
| Paclitaxel | 3 | 2022 | 460 | 0.130 |
Why?
|
| Global Health | 1 | 2016 | 193 | 0.130 |
Why?
|
| Chemotaxis | 2 | 2007 | 72 | 0.130 |
Why?
|
| Intellectual Disability | 2 | 2016 | 186 | 0.130 |
Why?
|
| Choristoma | 1 | 1995 | 68 | 0.130 |
Why?
|
| Meningioma | 1 | 1995 | 60 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2017 | 372 | 0.130 |
Why?
|
| Myxovirus Resistance Proteins | 1 | 2014 | 7 | 0.130 |
Why?
|
| Indazoles | 1 | 2015 | 68 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 4 | 2021 | 552 | 0.130 |
Why?
|
| Cherubism | 1 | 2014 | 1 | 0.130 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2014 | 302 | 0.130 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2018 | 579 | 0.120 |
Why?
|
| Iodine Radioisotopes | 1 | 2015 | 134 | 0.120 |
Why?
|
| Antigens, Nuclear | 1 | 2014 | 25 | 0.120 |
Why?
|
| Odontogenic Tumors | 1 | 2014 | 11 | 0.120 |
Why?
|
| MicroRNAs | 2 | 2010 | 534 | 0.120 |
Why?
|
| Myxoma | 1 | 2014 | 28 | 0.120 |
Why?
|
| Hematologic Neoplasms | 1 | 2018 | 329 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2017 | 860 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2019 | 2271 | 0.120 |
Why?
|
| Skin | 4 | 2006 | 554 | 0.120 |
Why?
|
| Transcriptome | 2 | 2015 | 580 | 0.120 |
Why?
|
| Imidazoles | 1 | 2015 | 162 | 0.120 |
Why?
|
| Blood Platelets | 1 | 2014 | 149 | 0.120 |
Why?
|
| GATA3 Transcription Factor | 1 | 2013 | 48 | 0.120 |
Why?
|
| Vascular Calcification | 1 | 2014 | 39 | 0.120 |
Why?
|
| Radiopharmaceuticals | 1 | 2015 | 180 | 0.120 |
Why?
|
| Proteomics | 1 | 2015 | 212 | 0.120 |
Why?
|
| Cornea | 3 | 2001 | 69 | 0.120 |
Why?
|
| Cell Division | 3 | 2003 | 696 | 0.120 |
Why?
|
| Computational Biology | 3 | 2015 | 528 | 0.120 |
Why?
|
| Drug Synergism | 3 | 2011 | 303 | 0.120 |
Why?
|
| Chondroma | 1 | 1993 | 8 | 0.120 |
Why?
|
| Carcinoma, Papillary | 1 | 2015 | 158 | 0.120 |
Why?
|
| Vero Cells | 5 | 1996 | 100 | 0.120 |
Why?
|
| Lip Neoplasms | 3 | 2021 | 8 | 0.120 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2013 | 33 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2012 | 683 | 0.110 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 3640 | 0.110 |
Why?
|
| STAT3 Transcription Factor | 2 | 2010 | 78 | 0.110 |
Why?
|
| Quality of Life | 3 | 2022 | 1585 | 0.110 |
Why?
|
| E2F3 Transcription Factor | 1 | 2012 | 2 | 0.110 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2012 | 11 | 0.110 |
Why?
|
| Integrin alpha4 | 1 | 2012 | 11 | 0.110 |
Why?
|
| Viral Proteins | 1 | 1995 | 300 | 0.110 |
Why?
|
| Sp1 Transcription Factor | 1 | 2012 | 19 | 0.110 |
Why?
|
| Proportional Hazards Models | 2 | 2022 | 859 | 0.110 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2012 | 18 | 0.110 |
Why?
|
| Quinolones | 3 | 2021 | 60 | 0.110 |
Why?
|
| CD11b Antigen | 1 | 2012 | 36 | 0.110 |
Why?
|
| Phosphorylation | 2 | 2012 | 1106 | 0.110 |
Why?
|
| Mouth Floor | 1 | 2012 | 4 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 266 | 0.110 |
Why?
|
| Genomics | 2 | 2018 | 720 | 0.110 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2013 | 213 | 0.110 |
Why?
|
| RNA Polymerase II | 1 | 2012 | 55 | 0.110 |
Why?
|
| Collagen Type I | 1 | 2012 | 62 | 0.110 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2012 | 63 | 0.110 |
Why?
|
| Parents | 1 | 2015 | 272 | 0.110 |
Why?
|
| Case-Control Studies | 4 | 2018 | 1805 | 0.110 |
Why?
|
| Antigens, CD | 1 | 2014 | 458 | 0.110 |
Why?
|
| Cisplatin | 3 | 2022 | 612 | 0.110 |
Why?
|
| Reproducibility of Results | 4 | 2019 | 2705 | 0.110 |
Why?
|
| Endodontics | 1 | 2012 | 1 | 0.110 |
Why?
|
| Curriculum | 1 | 2017 | 539 | 0.110 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2012 | 94 | 0.110 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2013 | 128 | 0.110 |
Why?
|
| Radiography, Dental | 1 | 2012 | 8 | 0.110 |
Why?
|
| DNA Helicases | 1 | 2012 | 79 | 0.110 |
Why?
|
| Tolonium Chloride | 2 | 2012 | 5 | 0.110 |
Why?
|
| Child | 7 | 2019 | 6927 | 0.110 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2014 | 379 | 0.110 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2013 | 164 | 0.100 |
Why?
|
| Phosphatidylinositol 3-Kinases | 4 | 2015 | 262 | 0.100 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2012 | 41 | 0.100 |
Why?
|
| Indoles | 2 | 2011 | 318 | 0.100 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2016 | 458 | 0.100 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2012 | 67 | 0.100 |
Why?
|
| Omentum | 1 | 2012 | 71 | 0.100 |
Why?
|
| Leiomyoma | 1 | 1995 | 191 | 0.100 |
Why?
|
| Gingiva | 2 | 2002 | 8 | 0.100 |
Why?
|
| Light | 3 | 2021 | 289 | 0.100 |
Why?
|
| Dental Research | 1 | 2011 | 1 | 0.100 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2012 | 105 | 0.100 |
Why?
|
| DNA Methylation | 2 | 2016 | 628 | 0.100 |
Why?
|
| DNA Mutational Analysis | 4 | 2017 | 526 | 0.100 |
Why?
|
| Carcinogenesis | 1 | 2013 | 195 | 0.100 |
Why?
|
| Mucous Membrane | 1 | 2011 | 83 | 0.100 |
Why?
|
| Receptors, Growth Factor | 2 | 2009 | 52 | 0.100 |
Why?
|
| Coronary Artery Disease | 1 | 2015 | 350 | 0.100 |
Why?
|
| Societies, Medical | 1 | 2015 | 572 | 0.100 |
Why?
|
| Bias | 2 | 2021 | 127 | 0.100 |
Why?
|
| Nuclear Localization Signals | 1 | 2010 | 10 | 0.100 |
Why?
|
| Cohort Studies | 4 | 2020 | 2767 | 0.100 |
Why?
|
| Pyruvate Kinase | 1 | 2010 | 13 | 0.100 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2017 | 592 | 0.090 |
Why?
|
| Young Adult | 5 | 2022 | 5976 | 0.090 |
Why?
|
| Neoplasm Proteins | 2 | 2012 | 532 | 0.090 |
Why?
|
| Retinoid X Receptor alpha | 1 | 2010 | 7 | 0.090 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2014 | 426 | 0.090 |
Why?
|
| Epigenomics | 1 | 2011 | 100 | 0.090 |
Why?
|
| Immunoblotting | 3 | 2017 | 268 | 0.090 |
Why?
|
| Thyroid Neoplasms | 1 | 2015 | 408 | 0.090 |
Why?
|
| Skin Transplantation | 2 | 2002 | 172 | 0.090 |
Why?
|
| Cell Survival | 4 | 2016 | 969 | 0.090 |
Why?
|
| Peptide Fragments | 1 | 2012 | 460 | 0.090 |
Why?
|
| Esophageal Neoplasms | 1 | 2012 | 321 | 0.090 |
Why?
|
| Incidence | 3 | 2022 | 1577 | 0.090 |
Why?
|
| Forecasting | 1 | 2011 | 304 | 0.090 |
Why?
|
| MAP Kinase Kinase 5 | 1 | 2009 | 11 | 0.090 |
Why?
|
| Feasibility Studies | 3 | 2022 | 751 | 0.090 |
Why?
|
| rap1 GTP-Binding Proteins | 1 | 2009 | 13 | 0.090 |
Why?
|
| Sirolimus | 1 | 2011 | 169 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 1 | 2009 | 21 | 0.090 |
Why?
|
| Dentistry | 1 | 2009 | 5 | 0.090 |
Why?
|
| Thrombospondins | 1 | 2009 | 14 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2008 | 189 | 0.090 |
Why?
|
| Cell Growth Processes | 4 | 2014 | 83 | 0.090 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2013 | 383 | 0.090 |
Why?
|
| Early Diagnosis | 1 | 2010 | 131 | 0.090 |
Why?
|
| Survival Rate | 3 | 2019 | 1863 | 0.090 |
Why?
|
| Dentist-Patient Relations | 1 | 2009 | 3 | 0.090 |
Why?
|
| Rats | 4 | 2001 | 3990 | 0.090 |
Why?
|
| Ki-67 Antigen | 1 | 2009 | 64 | 0.090 |
Why?
|
| Membrane Proteins | 2 | 2013 | 1196 | 0.090 |
Why?
|
| Piperidines | 1 | 2010 | 181 | 0.090 |
Why?
|
| Peptides | 2 | 2021 | 639 | 0.090 |
Why?
|
| Skin Neoplasms | 3 | 2015 | 546 | 0.090 |
Why?
|
| Protein Kinase C-alpha | 1 | 2009 | 27 | 0.090 |
Why?
|
| Sex Factors | 1 | 2012 | 1054 | 0.080 |
Why?
|
| Kidney Neoplasms | 1 | 2014 | 621 | 0.080 |
Why?
|
| Models, Biological | 2 | 2017 | 1749 | 0.080 |
Why?
|
| Culture Media, Conditioned | 2 | 2001 | 104 | 0.080 |
Why?
|
| Smoking | 3 | 2016 | 609 | 0.080 |
Why?
|
| Cattle | 3 | 1998 | 376 | 0.080 |
Why?
|
| Treatment Outcome | 6 | 2022 | 7993 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 2601 | 0.080 |
Why?
|
| United States Food and Drug Administration | 1 | 2009 | 127 | 0.080 |
Why?
|
| American Medical Association | 1 | 2008 | 17 | 0.080 |
Why?
|
| Cytokines | 3 | 2017 | 776 | 0.080 |
Why?
|
| Sequence Analysis, DNA | 3 | 2018 | 853 | 0.080 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 1208 | 0.080 |
Why?
|
| Hydroxyurea | 2 | 2022 | 239 | 0.080 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2008 | 57 | 0.080 |
Why?
|
| Up-Regulation | 4 | 2014 | 712 | 0.080 |
Why?
|
| Mice, Transgenic | 3 | 2018 | 1540 | 0.080 |
Why?
|
| Quality Improvement | 1 | 2012 | 428 | 0.080 |
Why?
|
| Infant | 4 | 2015 | 3046 | 0.080 |
Why?
|
| Epithelial Cells | 1 | 2012 | 669 | 0.080 |
Why?
|
| Spectrophotometry | 1 | 2007 | 106 | 0.080 |
Why?
|
| Paxillin | 1 | 2008 | 59 | 0.080 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2008 | 84 | 0.080 |
Why?
|
| Maximum Tolerated Dose | 2 | 2022 | 270 | 0.080 |
Why?
|
| Telomere-Binding Proteins | 1 | 2007 | 14 | 0.080 |
Why?
|
| Fluorescence | 1 | 2007 | 102 | 0.080 |
Why?
|
| Risk Assessment | 2 | 2016 | 2261 | 0.080 |
Why?
|
| Adenylyl Cyclases | 1 | 2007 | 100 | 0.070 |
Why?
|
| Punishment | 1 | 2006 | 10 | 0.070 |
Why?
|
| Recombinant Proteins | 3 | 2011 | 1014 | 0.070 |
Why?
|
| Opioid Peptides | 1 | 2006 | 5 | 0.070 |
Why?
|
| DNA | 1 | 2012 | 1294 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2013 | 1195 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2014 | 322 | 0.070 |
Why?
|
| Interprofessional Relations | 1 | 2007 | 121 | 0.070 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 2 | 2015 | 9 | 0.070 |
Why?
|
| Uteroglobin | 1 | 2006 | 4 | 0.070 |
Why?
|
| Fluorouracil | 2 | 2022 | 556 | 0.070 |
Why?
|
| Epidermal Growth Factor | 1 | 2006 | 119 | 0.070 |
Why?
|
| Prospective Studies | 3 | 2022 | 4213 | 0.070 |
Why?
|
| Antibodies | 1 | 2008 | 350 | 0.070 |
Why?
|
| Fibronectins | 1 | 2006 | 93 | 0.070 |
Why?
|
| Fibrosis | 1 | 2006 | 203 | 0.070 |
Why?
|
| Cytoplasm | 2 | 2017 | 281 | 0.070 |
Why?
|
| Gingival Recession | 2 | 2002 | 2 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2006 | 222 | 0.070 |
Why?
|
| Ovarian Neoplasms | 1 | 2012 | 744 | 0.070 |
Why?
|
| Tissue Distribution | 2 | 2022 | 290 | 0.070 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2019 | 70 | 0.070 |
Why?
|
| Protein Kinase C | 1 | 2006 | 270 | 0.070 |
Why?
|
| Giant Cells | 2 | 1996 | 19 | 0.070 |
Why?
|
| Restriction Mapping | 2 | 1995 | 157 | 0.060 |
Why?
|
| Gene Dosage | 3 | 2012 | 207 | 0.060 |
Why?
|
| Epithelium | 2 | 2015 | 319 | 0.060 |
Why?
|
| Methylation | 2 | 2017 | 251 | 0.060 |
Why?
|
| Naltrexone | 1 | 2006 | 135 | 0.060 |
Why?
|
| Mesocricetus | 2 | 2012 | 107 | 0.060 |
Why?
|
| Protein Binding | 3 | 2017 | 1456 | 0.060 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2015 | 56 | 0.060 |
Why?
|
| Time Factors | 4 | 2019 | 5210 | 0.060 |
Why?
|
| Serpins | 1 | 2004 | 29 | 0.060 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2019 | 456 | 0.060 |
Why?
|
| Angiostatins | 1 | 2003 | 15 | 0.060 |
Why?
|
| Recombination, Genetic | 2 | 1997 | 439 | 0.060 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2016 | 272 | 0.060 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2023 | 34 | 0.060 |
Why?
|
| Genetic Markers | 2 | 2003 | 476 | 0.060 |
Why?
|
| Pilot Projects | 1 | 2006 | 839 | 0.060 |
Why?
|
| Histones | 2 | 2016 | 311 | 0.060 |
Why?
|
| Heparin | 3 | 2006 | 175 | 0.060 |
Why?
|
| Human Genome Project | 1 | 2003 | 19 | 0.060 |
Why?
|
| Matched-Pair Analysis | 1 | 2003 | 43 | 0.060 |
Why?
|
| Survival Analysis | 3 | 2014 | 1538 | 0.060 |
Why?
|
| Blotting, Western | 3 | 2012 | 782 | 0.060 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 2002 | 23 | 0.060 |
Why?
|
| Mass Spectrometry | 2 | 2015 | 188 | 0.060 |
Why?
|
| Gene Frequency | 2 | 2018 | 677 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 376 | 0.050 |
Why?
|
| Chromosome Mapping | 1 | 2006 | 1074 | 0.050 |
Why?
|
| Combined Modality Therapy | 2 | 2010 | 1686 | 0.050 |
Why?
|
| Capillaries | 1 | 2003 | 91 | 0.050 |
Why?
|
| Macrophage Activation | 1 | 2002 | 46 | 0.050 |
Why?
|
| Epithelial Attachment | 1 | 2002 | 1 | 0.050 |
Why?
|
| Salivary Ducts | 1 | 2002 | 3 | 0.050 |
Why?
|
| Adenolymphoma | 1 | 2002 | 3 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 3 | 2009 | 1376 | 0.050 |
Why?
|
| Lasers | 1 | 2002 | 106 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2011 | 1075 | 0.050 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2023 | 165 | 0.050 |
Why?
|
| Oral Surgical Procedures | 1 | 2002 | 19 | 0.050 |
Why?
|
| Parotid Neoplasms | 1 | 2002 | 17 | 0.050 |
Why?
|
| Protein Biosynthesis | 1 | 2004 | 378 | 0.050 |
Why?
|
| Albumins | 1 | 2022 | 133 | 0.050 |
Why?
|
| Chronic Disease | 2 | 2016 | 971 | 0.050 |
Why?
|
| Interleukin-1 | 1 | 2001 | 71 | 0.050 |
Why?
|
| Chemokine CCL2 | 1 | 2001 | 47 | 0.050 |
Why?
|
| Lymphocyte Count | 1 | 2021 | 94 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2016 | 916 | 0.050 |
Why?
|
| Lymphocyte Depletion | 1 | 2021 | 97 | 0.050 |
Why?
|
| Histocytochemistry | 1 | 2001 | 130 | 0.050 |
Why?
|
| HeLa Cells | 2 | 2014 | 498 | 0.050 |
Why?
|
| Clone Cells | 1 | 2021 | 213 | 0.050 |
Why?
|
| Models, Animal | 1 | 2022 | 263 | 0.050 |
Why?
|
| Connective Tissue | 2 | 2002 | 23 | 0.050 |
Why?
|
| Coculture Techniques | 1 | 2001 | 164 | 0.050 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2001 | 87 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 2 | 2012 | 303 | 0.050 |
Why?
|
| Microcirculation | 1 | 2001 | 106 | 0.050 |
Why?
|
| Cell Cycle | 2 | 2016 | 502 | 0.050 |
Why?
|
| Monocytes | 1 | 2002 | 214 | 0.050 |
Why?
|
| Bacterial Proteins | 1 | 2007 | 864 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2010 | 557 | 0.050 |
Why?
|
| Gingivoplasty | 1 | 2000 | 1 | 0.050 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2013 | 182 | 0.050 |
Why?
|
| RNA, Small Interfering | 2 | 2015 | 547 | 0.050 |
Why?
|
| California | 1 | 2020 | 138 | 0.050 |
Why?
|
| Dentinogenesis | 1 | 2000 | 1 | 0.050 |
Why?
|
| Dentin | 1 | 2000 | 6 | 0.050 |
Why?
|
| Alendronate | 1 | 2000 | 12 | 0.050 |
Why?
|
| Salivary Glands | 1 | 1999 | 18 | 0.050 |
Why?
|
| Dental Service, Hospital | 1 | 2019 | 2 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2000 | 235 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 2019 | 62 | 0.040 |
Why?
|
| Leukocytes | 1 | 2001 | 202 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2019 | 1961 | 0.040 |
Why?
|
| Societies | 1 | 2019 | 12 | 0.040 |
Why?
|
| Triazines | 1 | 2000 | 53 | 0.040 |
Why?
|
| Sulfonamides | 2 | 2014 | 300 | 0.040 |
Why?
|
| Bone Marrow | 1 | 2001 | 435 | 0.040 |
Why?
|
| Tight Junctions | 2 | 2011 | 149 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 2021 | 325 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2001 | 312 | 0.040 |
Why?
|
| Probability | 1 | 2000 | 355 | 0.040 |
Why?
|
| Face | 1 | 2020 | 114 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 2 | 2002 | 927 | 0.040 |
Why?
|
| Nitric Oxide Synthase | 1 | 1999 | 125 | 0.040 |
Why?
|
| Image Cytometry | 1 | 2018 | 12 | 0.040 |
Why?
|
| Wounds and Injuries | 1 | 2002 | 231 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 1036 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 674 | 0.040 |
Why?
|
| Awareness | 1 | 2019 | 93 | 0.040 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2019 | 66 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2002 | 503 | 0.040 |
Why?
|
| Cell Fusion | 2 | 1995 | 39 | 0.040 |
Why?
|
| Exons | 1 | 2000 | 450 | 0.040 |
Why?
|
| Retinoids | 1 | 1998 | 17 | 0.040 |
Why?
|
| Dental Care | 1 | 1998 | 11 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2019 | 260 | 0.040 |
Why?
|
| Drug Combinations | 1 | 1999 | 224 | 0.040 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2018 | 54 | 0.040 |
Why?
|
| Molecular Biology | 1 | 1999 | 89 | 0.040 |
Why?
|
| Pyrrolidinones | 1 | 2018 | 16 | 0.040 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2018 | 5 | 0.040 |
Why?
|
| Skull | 1 | 2020 | 249 | 0.040 |
Why?
|
| Interferons | 1 | 1998 | 133 | 0.040 |
Why?
|
| Encephalomyelitis | 1 | 1997 | 6 | 0.040 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2011 | 121 | 0.040 |
Why?
|
| Quinolines | 1 | 2018 | 95 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2018 | 315 | 0.040 |
Why?
|
| Germ Cells | 1 | 2018 | 126 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2014 | 3612 | 0.040 |
Why?
|
| Cheek | 1 | 1997 | 22 | 0.040 |
Why?
|
| Health Personnel | 1 | 2019 | 202 | 0.040 |
Why?
|
| Temperature | 2 | 1996 | 396 | 0.040 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2017 | 66 | 0.040 |
Why?
|
| Cell Adhesion | 2 | 2010 | 420 | 0.040 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2010 | 70 | 0.040 |
Why?
|
| Intersectoral Collaboration | 1 | 2016 | 10 | 0.040 |
Why?
|
| Motor Disorders | 1 | 2016 | 7 | 0.040 |
Why?
|
| Granuloma, Pyogenic | 1 | 1996 | 5 | 0.040 |
Why?
|
| Receptors, Androgen | 1 | 2017 | 113 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 238 | 0.040 |
Why?
|
| Captopril | 1 | 1996 | 20 | 0.040 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2017 | 86 | 0.040 |
Why?
|
| Genotype | 2 | 2012 | 1851 | 0.040 |
Why?
|
| Maxilla | 1 | 1996 | 19 | 0.040 |
Why?
|
| Keratins | 1 | 1996 | 63 | 0.040 |
Why?
|
| Medicaid | 1 | 2019 | 217 | 0.040 |
Why?
|
| Neutralization Tests | 1 | 1996 | 77 | 0.040 |
Why?
|
| Receptors, Progesterone | 1 | 2017 | 167 | 0.040 |
Why?
|
| DNA Replication | 1 | 2017 | 164 | 0.030 |
Why?
|
| Drug Implants | 1 | 1996 | 34 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2016 | 133 | 0.030 |
Why?
|
| Lysine | 1 | 2017 | 147 | 0.030 |
Why?
|
| Fibrosarcoma | 1 | 1996 | 84 | 0.030 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2015 | 19 | 0.030 |
Why?
|
| Myofibromatosis | 1 | 1995 | 3 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2019 | 339 | 0.030 |
Why?
|
| Genome, Viral | 1 | 1996 | 74 | 0.030 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 1995 | 7 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2016 | 130 | 0.030 |
Why?
|
| Vimentin | 1 | 1995 | 44 | 0.030 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2015 | 74 | 0.030 |
Why?
|
| Papilloma | 1 | 2015 | 22 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2013 | 865 | 0.030 |
Why?
|
| Disabled Persons | 1 | 2016 | 67 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2016 | 211 | 0.030 |
Why?
|
| Meninges | 1 | 1995 | 13 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2017 | 384 | 0.030 |
Why?
|
| Age Factors | 1 | 2000 | 1851 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2015 | 137 | 0.030 |
Why?
|
| Benzocycloheptenes | 1 | 2015 | 2 | 0.030 |
Why?
|
| RNA | 2 | 2014 | 560 | 0.030 |
Why?
|
| Interferon Regulatory Factors | 1 | 2015 | 67 | 0.030 |
Why?
|
| Protein Transport | 1 | 2017 | 411 | 0.030 |
Why?
|
| Valine | 1 | 1995 | 69 | 0.030 |
Why?
|
| Viral Plaque Assay | 1 | 1995 | 19 | 0.030 |
Why?
|
| Alanine | 1 | 1995 | 85 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2015 | 24 | 0.030 |
Why?
|
| Genome, Human | 2 | 2010 | 756 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2015 | 104 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2016 | 256 | 0.030 |
Why?
|
| Mutagenesis, Insertional | 1 | 2015 | 111 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2016 | 468 | 0.030 |
Why?
|
| NIMA-Related Kinases | 1 | 2014 | 7 | 0.030 |
Why?
|
| Th2 Cells | 1 | 2016 | 146 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 1996 | 231 | 0.030 |
Why?
|
| Cricetulus | 1 | 1995 | 126 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2015 | 78 | 0.030 |
Why?
|
| Membrane Fusion | 1 | 1995 | 37 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2015 | 179 | 0.030 |
Why?
|
| Demography | 1 | 2015 | 177 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2018 | 533 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2021 | 3092 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2015 | 369 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2016 | 439 | 0.030 |
Why?
|
| Signaling Lymphocytic Activation Molecule Family | 1 | 2014 | 15 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 1996 | 269 | 0.030 |
Why?
|
| Human papillomavirus 18 | 1 | 2014 | 16 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2015 | 2357 | 0.030 |
Why?
|
| DNA Transposable Elements | 1 | 2015 | 169 | 0.030 |
Why?
|
| Gene Amplification | 1 | 2015 | 131 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 426 | 0.030 |
Why?
|
| Platelet Aggregation | 1 | 2014 | 44 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2015 | 196 | 0.030 |
Why?
|
| Tamoxifen | 1 | 2015 | 168 | 0.030 |
Why?
|
| Triazoles | 1 | 2015 | 96 | 0.030 |
Why?
|
| Antigen Presentation | 1 | 2015 | 209 | 0.030 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2014 | 6 | 0.030 |
Why?
|
| Protein Interaction Maps | 1 | 2014 | 48 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2014 | 77 | 0.030 |
Why?
|
| Autophagy-Related Protein 7 | 1 | 2014 | 12 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 684 | 0.030 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2014 | 26 | 0.030 |
Why?
|
| Sequestosome-1 Protein | 1 | 2014 | 22 | 0.030 |
Why?
|
| Radiation Tolerance | 1 | 2015 | 168 | 0.030 |
Why?
|
| Collagen | 1 | 1995 | 269 | 0.030 |
Why?
|
| High-Throughput Screening Assays | 1 | 2014 | 55 | 0.030 |
Why?
|
| Quinoxalines | 1 | 2014 | 50 | 0.030 |
Why?
|
| DNA Primers | 1 | 2014 | 543 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 294 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 455 | 0.030 |
Why?
|
| Cyclooxygenase 2 | 1 | 2013 | 100 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2014 | 217 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2015 | 728 | 0.030 |
Why?
|
| Ribonucleoproteins | 1 | 2012 | 38 | 0.030 |
Why?
|
| Fixatives | 1 | 2012 | 12 | 0.030 |
Why?
|
| Comorbidity | 1 | 2016 | 943 | 0.030 |
Why?
|
| Retreatment | 1 | 2012 | 107 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2012 | 92 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2012 | 63 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2012 | 40 | 0.030 |
Why?
|
| Culture Techniques | 2 | 2004 | 91 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 1 | 2013 | 114 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2012 | 78 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2012 | 52 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2015 | 425 | 0.030 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2012 | 35 | 0.030 |
Why?
|
| Acute Disease | 1 | 2014 | 826 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2013 | 199 | 0.030 |
Why?
|
| Autophagy | 1 | 2014 | 149 | 0.030 |
Why?
|
| Los Angeles | 1 | 2012 | 28 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2012 | 216 | 0.030 |
Why?
|
| Failure to Thrive | 1 | 2012 | 17 | 0.030 |
Why?
|
| Asymptomatic Diseases | 1 | 2012 | 41 | 0.030 |
Why?
|
| Cytoprotection | 1 | 2012 | 47 | 0.030 |
Why?
|
| Breast Neoplasms | 2 | 2015 | 2903 | 0.030 |
Why?
|
| Binding Sites | 1 | 1995 | 1098 | 0.030 |
Why?
|
| Sulfites | 1 | 2012 | 26 | 0.030 |
Why?
|
| Barrett Esophagus | 1 | 2012 | 93 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2012 | 104 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2013 | 289 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 2012 | 307 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2013 | 159 | 0.030 |
Why?
|
| Receptor, Cholecystokinin B | 1 | 2011 | 3 | 0.030 |
Why?
|
| Colonic Neoplasms | 1 | 1996 | 556 | 0.030 |
Why?
|
| Microcephaly | 1 | 2012 | 75 | 0.030 |
Why?
|
| Viral Load | 1 | 2012 | 148 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 364 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2012 | 176 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2016 | 1823 | 0.030 |
Why?
|
| Physical Examination | 1 | 2012 | 149 | 0.020 |
Why?
|
| Adherens Junctions | 1 | 2011 | 34 | 0.020 |
Why?
|
| Commiphora | 1 | 2010 | 1 | 0.020 |
Why?
|
| Plant Gums | 1 | 2010 | 1 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2012 | 172 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2012 | 232 | 0.020 |
Why?
|
| B7-H1 Antigen | 1 | 2013 | 250 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2013 | 444 | 0.020 |
Why?
|
| Animal Feed | 1 | 2010 | 20 | 0.020 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2012 | 173 | 0.020 |
Why?
|
| Benzodiazepines | 1 | 2011 | 65 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2012 | 174 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2011 | 316 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 2012 | 646 | 0.020 |
Why?
|
| Observer Variation | 1 | 2012 | 602 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2010 | 116 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2010 | 75 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2011 | 114 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2012 | 342 | 0.020 |
Why?
|
| Review Literature as Topic | 1 | 2010 | 21 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2011 | 391 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2011 | 192 | 0.020 |
Why?
|
| Linear Models | 1 | 2011 | 421 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2010 | 279 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2014 | 395 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2010 | 86 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2010 | 205 | 0.020 |
Why?
|
| Inhibitor of Differentiation Protein 1 | 1 | 2009 | 8 | 0.020 |
Why?
|
| Radiosurgery | 1 | 2013 | 272 | 0.020 |
Why?
|
| Protein Interaction Mapping | 1 | 2010 | 82 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2009 | 96 | 0.020 |
Why?
|
| Protein Engineering | 1 | 2010 | 140 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2009 | 100 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2012 | 267 | 0.020 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2009 | 113 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2009 | 115 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2011 | 615 | 0.020 |
Why?
|
| Kidney | 1 | 1995 | 1241 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 912 | 0.020 |
Why?
|
| Cyclin E | 1 | 2009 | 27 | 0.020 |
Why?
|
| Ubiquitin | 1 | 2009 | 93 | 0.020 |
Why?
|
| Plant Extracts | 1 | 2010 | 244 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2009 | 281 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2016 | 2501 | 0.020 |
Why?
|
| Genes, erbB-1 | 1 | 2008 | 16 | 0.020 |
Why?
|
| Chemokine CXCL1 | 1 | 2007 | 9 | 0.020 |
Why?
|
| Asthma | 1 | 2016 | 955 | 0.020 |
Why?
|
| Glioblastoma | 1 | 2010 | 255 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2013 | 629 | 0.020 |
Why?
|
| ras Guanine Nucleotide Exchange Factors | 1 | 2007 | 8 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2008 | 307 | 0.020 |
Why?
|
| Receptors, Peptide | 1 | 2007 | 16 | 0.020 |
Why?
|
| Piperazines | 1 | 2009 | 272 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2007 | 252 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2009 | 736 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 1169 | 0.020 |
Why?
|
| Morphine Derivatives | 1 | 2006 | 8 | 0.020 |
Why?
|
| Benzophenanthridines | 1 | 2006 | 23 | 0.020 |
Why?
|
| Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 1 | 2006 | 22 | 0.020 |
Why?
|
| Butadienes | 1 | 2006 | 33 | 0.020 |
Why?
|
| Phenanthridines | 1 | 2006 | 24 | 0.020 |
Why?
|
| Antigens, Bacterial | 1 | 2007 | 134 | 0.020 |
Why?
|
| RNA Interference | 1 | 2008 | 369 | 0.020 |
Why?
|
| Bacterial Toxins | 1 | 2007 | 111 | 0.020 |
Why?
|
| Alkaloids | 1 | 2006 | 45 | 0.020 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2006 | 79 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 2007 | 273 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2006 | 145 | 0.020 |
Why?
|
| Transglutaminases | 1 | 2006 | 39 | 0.020 |
Why?
|
| Nitriles | 1 | 2006 | 149 | 0.020 |
Why?
|
| Cytoskeleton | 1 | 2007 | 193 | 0.020 |
Why?
|
| Drug Resistance, Microbial | 2 | 1996 | 72 | 0.020 |
Why?
|
| Morphine | 1 | 2006 | 130 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2006 | 280 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2012 | 1169 | 0.020 |
Why?
|
| Mutagenesis | 2 | 1996 | 199 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2006 | 692 | 0.020 |
Why?
|
| Narcotic Antagonists | 1 | 2006 | 154 | 0.020 |
Why?
|
| Cell Differentiation | 2 | 2002 | 1458 | 0.020 |
Why?
|
| Evolution, Molecular | 1 | 2010 | 813 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2009 | 930 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2004 | 268 | 0.010 |
Why?
|
| Cellular Senescence | 1 | 2004 | 94 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2006 | 881 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2006 | 666 | 0.010 |
Why?
|
| Dissection | 1 | 2002 | 42 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2002 | 245 | 0.010 |
Why?
|
| Skin, Artificial | 1 | 2002 | 8 | 0.010 |
Why?
|
| Gene Library | 1 | 2002 | 130 | 0.010 |
Why?
|
| Fibrillar Collagens | 1 | 2002 | 10 | 0.010 |
Why?
|
| Elastic Tissue | 1 | 2002 | 18 | 0.010 |
Why?
|
| Neuropilin-1 | 1 | 2002 | 14 | 0.010 |
Why?
|
| Dermis | 1 | 2002 | 27 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2002 | 393 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2002 | 285 | 0.010 |
Why?
|
| Regeneration | 1 | 2002 | 143 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2002 | 270 | 0.010 |
Why?
|
| Periodontal Pocket | 1 | 2000 | 1 | 0.010 |
Why?
|
| Oral Hygiene | 1 | 2000 | 3 | 0.010 |
Why?
|
| Periodontal Attachment Loss | 1 | 2000 | 2 | 0.010 |
Why?
|
| Dental Plaque Index | 1 | 2000 | 3 | 0.010 |
Why?
|
| Periodontal Index | 1 | 2000 | 4 | 0.010 |
Why?
|
| Esthetics, Dental | 1 | 2000 | 2 | 0.010 |
Why?
|
| Freeze Drying | 1 | 2000 | 14 | 0.010 |
Why?
|
| Tissue Preservation | 1 | 2000 | 14 | 0.010 |
Why?
|
| Tooth Root | 1 | 2000 | 1 | 0.010 |
Why?
|
| Bicuspid | 1 | 2000 | 3 | 0.010 |
Why?
|
| Decalcification Technique | 1 | 2000 | 2 | 0.010 |
Why?
|
| Tetracycline | 1 | 2000 | 13 | 0.010 |
Why?
|
| Molar | 1 | 2000 | 21 | 0.010 |
Why?
|
| Culture Media | 1 | 2000 | 147 | 0.010 |
Why?
|
| Metaplasia | 1 | 1999 | 37 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2000 | 307 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 2000 | 331 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2000 | 238 | 0.010 |
Why?
|
| Proteins | 1 | 2004 | 777 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2000 | 242 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2000 | 425 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2002 | 926 | 0.010 |
Why?
|
| Potassium Chloride | 1 | 1996 | 87 | 0.010 |
Why?
|
| Graft Survival | 1 | 2000 | 884 | 0.010 |
Why?
|
| Metalloendopeptidases | 1 | 1996 | 45 | 0.010 |
Why?
|
| Viral Fusion Proteins | 1 | 1994 | 10 | 0.010 |
Why?
|
| Genes, Viral | 1 | 1994 | 116 | 0.010 |
Why?
|
| Kinetics | 1 | 1996 | 1513 | 0.010 |
Why?
|
| Cyclosporine | 1 | 1994 | 234 | 0.010 |
Why?
|